Livagen
Livagen is a peptide, indexed here under Short peptide bioregulators.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Short peptide bioregulators |
| CAS registry number | 433257-50-2[1] |
| PubChem CID | 87919683[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C18H31N5O9[1] |
| Molecular weight | 461.5 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala. A 2002 Bulletin of Experimental Biology and Medicine paper reports effects on chromatin activation in lymphocytes from old people, and a 2007 Georgian Medical News paper reports variability of the radiation-induced adaptive response in old-age individuals and its correction by the peptide, both in cultured cells.
The remaining records concern the liver and digestion: a 2001 Izvestiia Akademii Nauk paper on the rhythm of protein synthesis in hepatocyte cultures from rats of different ages, a 2002 Advances in Gerontology paper on the functional morphology of an organotypic liver culture, a 2005 paper in the same journal on digestive enzyme activity in rats of different ages, and a 2003 Izvestiia Akademii Nauk paper on livagen and epitalon and enkephalin-degrading enzymes in human serum.
[3, 4, 5, 6, 7, 8]Reported mechanism
A tetrapeptide bioregulator; the retrieved records report chromatin activation in lymphocytes and inhibition of enkephalin-degrading enzymes, with no receptor target named.
[3, 8]Stated in the titles of the cited 2002 Bulletin of Experimental Biology and Medicine and 2003 Izvestiia Akademii Nauk papers.
Targets named in the cited records: chromatin activation, enkephalin-degrading enzymes.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Livagen appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- Lys-Glu-Asp-Ala
- KEDA peptide
Where this page sits
Research records
Cited research records for Livagen, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
Class page: Short peptide bioregulators. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Livagen?
Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala. A 2002 Bulletin of Experimental Biology and Medicine paper reports effects on chromatin activation in lymphocytes from old people, and a 2007 Georgian Medical News paper reports variability of the radiation-induced adaptive response in old-age individuals and its correction by the peptide, both in cultured cells.
Which class is Livagen indexed under?
Livagen is indexed under Short peptide bioregulators. This class groups the short synthetic peptides and tissue polypeptide extracts developed by the St Petersburg bioregulator programme, which research-peptide catalogues sell as a family.
What does the FDA application register show for Livagen?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 87919683, Livagen. PubChem, National Library of Medicine (2026). pubchem:87919683
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:livagen
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of experimental biology and medicine (2002). pmid:12533768
- [Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen]. Georgian medical news (2007). pmid:17921545
- [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen]. Izvestiia Akademii nauk. Seriia biologicheskaia (2001). pmid:15926314
- [Functional morphology of an organotypic liver culture exposed to the peptide livagen]. Advances in gerontology = Uspekhi gerontologii (2002). pmid:12577697
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. Advances in gerontology = Uspekhi gerontologii (2005). pmid:16075683
- [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izvestiia Akademii nauk. Seriia biologicheskaia (2003). pmid:12942748
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.